Skip to main content

Part of UT Health San Antonio

Graduate School of Biomedical Sciences, UT Health San AntonioGraduate School of Biomedical Sciences, UT Health San Antonio

Part of UT Health San Antonio

Give
Search

Quicklinks

Commencement

  • Commencement 2021

Logins

  • Canvas
  • CourseLeaf
  • IMPACT
  • LiveMail
  • My UT Health (Intranet)

Resources

  • COVID-19 Updates for Students
  • Enrolled Student Resources
  • Educational Resources

 Close Quicklinks

 
Menu
  • About
  • Admissions
  • Programs
  • Research
  • Faculty
  • Student Life
  • Alumni

You are here

  • Faculty directory
  • James Freeman
James Freeman

Contact

210-567-5298

freemanjw@uthscsa.edu

Programs

Cancer Biology
Ph.D. in Integrated Biomedical Sciences

James  Freeman, Ph.D.

Professor

Hematology and Oncology

Research in Dr. James Freeman's lab focuses on basic and translational studies related to pathobiology and therapy of pancreatic cancer. Cancer cells undergo cellular plasticity in response to environmental stresses and chemotherapy. Plasticity involves a phenotypic switch with cells undergoing an epithelial to mesenchymal transition an expressing stem cell markers. 

The consequences of this switch are resistant to chemotherapy and more highly invasive cancer cell. Thus one adverse effect of chemotherapy can by the development of a subpopulation of cancer cells that are more aggressive. Our studies focus on understanding the molecular events that regulate this switch and development of strategies to block phenotypic switching as a means of improving therapy.

  • Publications

    Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW. Inhibiting signaltransducer and activator of transcription-3 increases response to gemcitabineand delays progression of pancreatic cancer.Mol Cancer. 2013 Sep 11;12(1):104.

    Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, Reddick R, Kopetz S, Peterson A, Wang H, Fischer SM, Kumar AP. Combined Targeting ofSTAT3/NF-κB/COX-2/EP4 for Effective Management of Pancreatic Cancer.Cancer Res. 2014 Mar 1;20(5):1259-73.

    Zhao S, Cao L, Freeman JW. Knockdown of RON receptorkinase delays but does not prevent tumor progression while enhancing HGF/METsignaling in pancreatic cancer cell lines. Oncogenesis. 2013 Oct 7;2:e76. 

    Carew JS, Espitia CM, Zhao W, Kelly KR, Coffey M, Freeman JW, Nawrocki ST. Reolysinis a novel reovirus-based agent that induces endoplasmic reticularstress-mediated apoptosis in pancreatic cancer. Cell Death Dis. 2013 Jul 18;4:e728.

    Bera A, Zhao S, Cao L, Chiao PJ, Freeman, JW. OncogenicK-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-κB Axis thatinduces expression of MMP9 and uPA in human pancreas progenitor cells. PLoS One. 2013 Dec 5;8(12):e82282.

Map image of UT Health San Antonio location
UT Health San Antonio
Graduate School of Biomedical Sciences

7703 Floyd Curl Drive

San Antonio, TX 78229

210-567-3709

gsbs@uthscsa.edu

  • About us
  • Contact us
  • Maps & directions

We make lives better ®

The University of Texas Health Science Center at San Antonio, also called UT Health San Antonio, is a leading academic health center with a mission to make lives better through excellence in advanced academics, life-saving research and comprehensive clinical care including health, dental and cancer services.

Web Privacy | Links from websites affiliated with UT Health's website (uthscsa.edu) to other websites do not constitute or imply university endorsement of those sites, their content, or products and services associated with those sites. The content on this website is intended to be used for informational purposes only. Health information on this site is not meant to be used to diagnose or treat conditions. Consult a health care provider if you are in need of treatment.